This document is copyrighted material.

 A copy is available for viewing in the OSHA Docket Office/Technical Data Center, FPB,

200 Constitution Avenue, Rm N2625,

Washington, DC 20210


Comment Info: =================

General Comment:Dear Mr. Zeller:

I am writing as an individual consumer to request an extension of the comment period for the Food and Drug Administration's ("FDA") Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act (the "Proposed Rule") published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. On behalf of myself, I am requesting that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days, from its current 75-day period, to 180 days.

The Proposed Rule raises a number of significant issues and questions that are important and relevant to me, as a consumer of products that are proposed for regulation under the Proposed Rule. The Proposed Rule asks about a hundred different questions I might want to respond to. I want to provide my thoughts and comments on many of these issues, but my time to devote to researching and providing thoughtful comments on these important questions is limited. I have already spent many hours researching and dissecting these issues, but they take time. I know that the FDA took many years to even come up with the Proposed Rule, so I do not think it is at all unreasonable to allow the public a mere six months to comment on it. This is our only opportunity, as consumers, to provide our feedback.

I have tried everything except prescription drugs to quit smoking.  The new technology has given me the miracle of being a non smoker for the first time ever in my life.  All the no smoking policies-the exorbitant taxes on tobacco make smokers feel like they are participating in an illegal activity-- Yet, at the same time you are imposing regulations that make the safer and healthier choice almost as impossible.  What is is you actually want???  Smokers or Non smokers?   I agree that bottles should be labeled because of the nicotine but where is the TOBACCO in these products?  How can a tobacco free product be scrutinized as Tobacco?

I appreciate your consideration of my request and am happy to discuss this issue with you further.


[Federal Register Volume 88, Number 134 (Friday, July 14, 2023)]
[Notices]
[Page 45205]
[FR Doc No: 2023-14937]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL OP-OFA-077]

Environmental Impact Statements; Notice of Availability

    Responsible Agency: Office of Federal Activities, General
Information<PHONE_NUMBER> or https://www.epa.gov/nepa.

Weekly receipt of Environmental Impact Statements (EIS)
Filed June 30, 2023 10 a.m. EST Through July 10, 2023 10 a.m. EST
Pursuant to 40 CFR 1506.9.

    Notice: Section 309(a) of the Clean Air Act requires that EPA make
public its comments on EISs issued by other Federal agencies. EPA's
comment letters on EISs are available at: https://cdxapps.epa.gov/cdx-enepa-II/public/action/eis/search.

EIS No. 20230084, Draft Supplement, USFS, ID, Crow Creek Pipeline
Project, Comment Period Ends: 10/12/2023, Contact: Robbert Mickelsen
208-557-5764.
EIS No. 20230085, Draft Supplement, USFS, UT, High Uintas Wilderness
Domestic Sheep Analysis, Comment Period Ends: 08/28/2023, Contact: Paul
Cowley<PHONE_NUMBER>.

    Dated: July 10, 2023.
Cindy S. Barger,
Director, NEPA Compliance Division, Office of Federal Activities.
[FR Doc. 2023-14937 Filed 7-13-23; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 80, Number 102 (Thursday, May 28, 2015)]
[Notices]
[Pages 30479-30480]
[FR Doc No: 2015-12913]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4217-DR; Docket ID FEMA-2015-0002]

Kentucky; Amendment No. 2 to Notice of a Major Disaster
Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster declaration
for the Commonwealth of Kentucky (FEMA-4217-DR), dated May 1, 2015, and
related determinations.

DATES: Effective May 21, 2015.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and
Recovery, Federal Emergency Management Agency, 500 C Street SW.,
Washington, DC 20472,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The notice of a major disaster declaration
for the Commonwealth of Kentucky is hereby amended to include the
following areas among those areas determined to have been adversely
affected by the event declared a major disaster by the President in his
declaration of May 1, 2015.

    Carter County for Public Assistance (already designated for
Individual Assistance). Floyd, Lincoln, Nicholas, Owen, Pike,
Spencer, and Whitley Counties for Public Assistance.

    The following Catalog of Federal Domestic Assistance Numbers
(CFDA) are to be used for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis
Counseling; 97.033, Disaster Legal Services; 97.034, Disaster
Unemployment Assistance (DUA); 97.046, Fire Management Assistance
Grant; 97.048, Disaster Housing Assistance to Individuals and
Households In Presidentially

Declared Disaster Areas; 97.049, Presidentially Declared Disaster
Assistance--Disaster Housing Operations for Individuals and
Households; 97.050 Presidentially Declared Disaster Assistance to
Individuals and Households--Other Needs; 97.036, Disaster Grants--
Public Assistance (Presidentially Declared Disasters); 97.039,
Hazard Mitigation Grant.

W. Craig Fugate,
Administrator, Federal Emergency Management Agency.
[FR Doc. 2015-12913 Filed 5-27-15; 8:45 am]
 BILLING CODE 9111-23-P


[Federal Register: March 11, 2010 (Volume 75, Number 47)]
[Notices]
[Page 11583-11584]
[DOCID:fr11mr10-96]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 29169; 812-13749]

The Chile Fund, Inc.; Notice of Application

March 8, 2010.
AGENCY: Securities and Exchange Commission (``Commission'').

ACTION: Notice of application for an order under section 17(b) of the
Investment Company Act of 1940 (the ``Act'') for an exemption from
section 17(a) of the Act.

-----------------------------------------------------------------------

Applicant: The Chile Fund, Inc. (the ``Fund'').
SUMMARY: Summary of Application: Applicant seeks an order that would
permit in-kind repurchases of shares of the Fund held by certain
affiliated shareholders of the Fund.

Dates: Filing Dates: The application was filed on January 29, 2010, and
amended on March 5, 2010. Applicants have agreed to file an amendment
during the notice period, the substance of which is reflected in this
notice.

Hearing or Notification of Hearing: An order granting the requested
relief will be issued unless the Commission orders a hearing.
Interested persons may request a hearing by writing to the Commission's
Secretary and serving applicants with a copy of the request, personally
or by mail. Hearing requests should be received by the Commission by
5:30 p.m. on March 29, 2010, and should be accompanied by proof of
service on applicants, in the form of an affidavit or, for lawyers, a
certificate of service. Hearing requests should state the nature of the
writer's interest, the reason for the request, and the issues
contested. Persons who wish to be notified of a hearing may request
notification by writing to the Commission's Secretary.

Addresses: Secretary, Securities and Exchange Commission, 100 F Street,
NE., Washington, DC 20549-1090. Applicant, c/o Aberdeen Asset
Management Inc., 1735 Market Street, 32nd Floor, Philadelphia, PA
19103.

For Further Information Contact: Bruce R. MacNeil, Senior Counsel, at
(202) 551-6817, or Julia Kim Gilmer, Branch Chief, at<PHONE_NUMBER>
(Division of Investment Management, Office of Investment Company
Regulation).

Supplementary Information: The following is a summary of the
application. The complete application may be obtained via the
Commission's Web site by searching for the file number, or an applicant
using the Company name box, at http://www.sec.gov/search/search.htm or
by calling<PHONE_NUMBER>.

Applicant's Representations

    1. The Fund, a Maryland corporation, is registered under the Act as
a closed-end management investment company. The Fund's investment
objective is to seek total return by investing primarily in Chilean
equity and debt securities. Applicant states that under normal
circumstances it invests at least 80% of its net assets in Chilean
equity and debt securities.\1\ Shares of the Fund are listed and trade
on the NYSE AMEX. Aberdeen Asset Management Investment Services Limited
(the ``Adviser''), an investment adviser registered under the
Investment Advisers Act of 1940, serves as the investment adviser to
the Fund.
---------------------------------------------------------------------------

    \1\ Applicant states that as of September 30, 2009,
approximately 99.4% of its assets were invested in equity securities
of Chilean issuers, 96.9% of which were listed on the Santiago Stock
Exchange.
---------------------------------------------------------------------------

    2. The Fund proposes to repurchase 25% of its outstanding shares at
99% of net asset value (``NAV'') on an in-kind basis with a pro rata
distribution of the Fund's portfolio securities (with exceptions
generally for odd lots, fractional shares, and cash items) (the ``In-
Kind Repurchase Offer''). The In-Kind Repurchase Offer will be made
pursuant to section 23(c)(2) of the Act and conducted in accordance
with rule 13e-4 under the Securities Exchange Act of 1934.
    3. Applicant states that the In-Kind Repurchase Offer is designed
to accommodate the needs of shareholders who wish to participate in the
In-Kind Repurchase Offer and long-term shareholders who would prefer to
remain invested in a closed-end investment vehicle. Under the In-Kind
Repurchase Offer, only participating shareholders will pay U.S. Federal
taxes

on the gain on appreciated securities distributed in the In-Kind
Repurchase Offer. Non-participating shareholders would avoid the
imposition of a significant Federal tax liability, which would occur if
the Fund sold the appreciated securities to make payments in cash.
Applicant further states that the In-Kind Repurchase Offer's in-kind
payments will minimize market disruption, while allowing the Fund to
avoid a cascade of distributions, required to preserve its tax status,
that would reduce the size of the Fund drastically. Applicant requests
relief to permit any common shareholder of the Fund who is an
``affiliated person'' of the Fund solely by reason of owning,
controlling, or holding with the power to vote, 5% or more of the
Fund's shares (``Affiliated Shareholder'') to participate in the
proposed In-Kind Repurchase Offer.

Applicant's Legal Analysis

    1. Section 17(a) of the Act prohibits an affiliated person of a
registered investment company, or any affiliated person of the person,
acting as principal, from knowingly purchasing or selling any security
or other property from or to the company. Section 2(a)(3) of the Act
defines an ``affiliated person'' of another person to include any
person who directly or indirectly owns, controls, or holds with power
to vote 5% or more of the outstanding voting securities of the other
person. Applicant states that to the extent that the In-Kind Repurchase
Offer could be deemed the purchase or sale of securities by an
Affiliated Shareholder, the transactions would be prohibited by section
17(a). Accordingly, applicant requests an exemption from section 17(a)
of the Act to the extent necessary to permit the participation of
Affiliated Shareholders in the In-Kind Repurchase Offer.
    2. Section 17(b) of the Act authorizes the Commission to exempt any
transaction from the provisions of section 17(a) if the terms of the
transaction, including the consideration to be paid or received, are
reasonable and fair and do not involve overreaching on the part of any
person concerned, and the transaction is consistent with the policy of
each registered investment company and with the general purposes of the
Act.
    3. Applicant asserts that the terms of the In-Kind Repurchase Offer
meet the requirements of sections 17(b) of the Act. Applicant asserts
that neither the Fund nor an Affiliated Shareholder has any choice as
to the portfolio securities to be received as proceeds from the In-Kind
Repurchase Offer. Instead, shareholders will receive their pro rata
portion of each of the Fund's portfolio securities, excluding (a)
securities which, if distributed, would have to be registered under the
Securities Act of 1933 (``Securities Act''), and (b) securities issued
by entities in countries which restrict or prohibit the holding of
securities by non-residents other than through qualified investment
vehicles, or whose distributions would otherwise be contrary to
applicable local laws, rules or regulations, and (c) certain portfolio
assets that involve the assumption of contractual obligations, require
special trading facilities, or may only be traded with the counterparty
to the transaction. Moreover, applicant states that the portfolio
securities to be distributed in the In-Kind Repurchase Offer will be
valued according to an objective, verifiable standard, and the In-Kind
Repurchase Offer is consistent with the investment policies of the
Fund. Applicant also believes that the In-Kind Repurchase Offer is
consistent with the general purposes of the Act because the interests
of all shareholders are equally protected and no Affiliated Shareholder
would receive an advantage or special benefit not available to any
other shareholder participating in the In-Kind Repurchase Offer.

Applicant's Conditions

    Applicant agrees that any order granting the requested relief will
be subject to the following conditions:
    1. Applicant will distribute to shareholders participating in the
In-Kind Repurchase Offer an in-kind pro rata distribution of portfolio
securities of applicant. The pro rata distribution will not include:
(a) Securities that, if distributed, would be required to be registered
under the Securities Act; (b) securities issued by entities in
countries that restrict or prohibit the holdings of securities by non-
residents other than through qualified investment vehicles, or whose
distribution would otherwise be contrary to applicable local laws,
rules or regulations; and (c) certain portfolio assets, such as
derivative instruments or repurchase agreements, that involve the
assumption of contractual obligations, require special trading
facilities, or can only be traded with the counterparty to the
transaction. Cash will be paid for that portion of applicant's assets
represented by cash and cash equivalents (such as certificates of
deposit, commercial paper and repurchase agreements) and other assets
which are not readily distributable (including receivables and prepaid
expenses), net of all liabilities (including accounts payable). In
addition, applicant will distribute cash in lieu of fractional shares
and accruals on such securities. Applicant may round down or up the
proportionate distribution of each portfolio security to the nearest
round lot amount so as to eliminate an odd lot prior to distribution
and will distribute the remaining value of the odd lot, if any, in
cash. Applicant may also distribute a higher pro rata percentage of
other portfolio securities to represent such fractional shares and odd
lots.
    2. The securities distributed to shareholders pursuant to the In-
Kind Repurchase Offer will be limited to securities that are traded on
a public securities market or for which quoted bid and asked prices are
available.
    3. The securities distributed to shareholders pursuant to the In-
Kind Repurchase Offer will be valued in the same manner as they would
be valued for purposes of computing applicant's net asset value, which,
in the case of securities traded on a public securities market for
which quotations are available, is their last reported sales price on
the exchange on which the securities are primarily traded or at the
last sales price on a public securities market, or, if the securities
are not listed on an exchange or a public securities market or if there
is no such reported price, the average of the most recent bid and asked
price (or, if no such asked price is available, the last quoted bid
price).
    4. Applicant will maintain and preserve for a period of not less
than six years from the end of the fiscal year in which the In-Kind
Repurchase Offer occurs, the first two years in an easily accessible
place, a written record of the In-Kind Repurchase Offer that includes
the identity of each shareholder of record that participated in the In-
Kind Repurchase Offer, whether that shareholder was an Affiliated
Shareholder, a description of each security distributed, the terms of
the distribution, and the information or materials upon which the
valuation was made.

    For the Commission, by the Division of Investment Management,
under delegated authority.
Florence E. Harmon,
Deputy Secretary.
[FR Doc. 2010-5235 Filed 3-10-10; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 88, Number 151 (Tuesday, August 8, 2023)]
[Notices]
[Pages 53501-53503]
[FR Doc No: 2023-16930]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-D-2439]

QTc Information in Human Prescription Drug and Biological Product
Labeling; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft guidance for industry entitled ``QTc
Information in Human Prescription Drug and Biological Product
Labeling.'' This guidance is intended to assist applicants with
incorporating corrected QT (QTc) interval prolongation-related
information into the labeling of non-antiarrhythmic human prescription
drug and biological products. The guidance provides recommendations on
how and where to appropriately include the clinically relevant
information on QTc interval prolongation in the labeling, in accordance
with regulatory requirements for the content and format of human
prescription drug labeling.

DATES: Submit either electronic or written comments on the draft
guidance by October 10, 2023 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your

comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2023-D-2439 for ``QTc Information in Human Prescription Drug and
Biological Product Labeling.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-
402-7500.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of the draft guidance to
the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10001 New Hampshire Ave.,
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002; or to the
Office of Communication, Outreach and Development, Center for Biologics
Evaluation and Research (CBER), Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. The draft guidance may also be obtained by mail by
calling CBER at 1-800-835-4709 or<PHONE_NUMBER>. See the SUPPLEMENTARY
INFORMATION section for electronic access to the draft guidance
document.

FOR FURTHER INFORMATION CONTACT: William Pierce, Oncology Center of
Excellence, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 22, Rm. 2159, Silver Spring, MD 20993,<PHONE_NUMBER>; or Diane
Maloney, Center for Biologics Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver
Spring, MD 20993,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a draft guidance for industry
entitled ``QTc Information in Human Prescription Drug and Biological
Product Labeling.'' This guidance is intended to assist applicants with
incorporating corrected QT (QTc) interval prolongation-related
information into the labeling of non-antiarrhythmic human prescription
drug and biological products. An undesirable property of some non-
antiarrhythmic drugs is their ability to delay cardiac repolarization.
A delay in cardiac repolarization creates an electrophysiological
environment that favors the development of torsade de pointes (TdP),
which can degenerate into ventricular fibrillation, leading to sudden
death. While the degree of QT prolongation is recognized as an
imperfect biomarker for proarrhythmic risk, in general, there is a
qualitative relationship between QT prolongation and the risk of TdP,
especially for drugs that cause prolongation of the QT interval due to
inhibition of the delayed rectifier potassium channel.
    FDA and the International Council for Harmonisation recommend that
applicants for most non-antiarrhythmic drugs with systemic
bioavailability assess effect on cardiac repolarization early in
clinical development including a clinical electrocardiographic
evaluation. The QTc assessment in early clinical development may inform
the intensity and continuation of electrocardiogram (ECG) monitoring in
late phase clinical trials. A finding of QTc interval prolongation in
early clinical development may support continuing ECG monitoring in
subsequent clinical trials. The guidance provides recommendations and
examples on how and where to appropriately include the clinically
relevant information on QTc interval prolongation in labeling, in
accordance with regulatory requirements for the content and format of
human prescription drug labeling.
    This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``QTc
Information in Human Prescription Drug and Biological Product
Labeling.'' It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

    While this guidance contains no collection of information, it does
refer to previously approved FDA collections of information. The
previously approved collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501-3521). The collections of information in 21
CFR 201.56 and 201.57 have been approved under OMB control number 0910-
0572; the collections of information in 21 CFR part 314 have been
approved under OMB control number 0910-0001; and the collections

of information in 21 CFR part 601 have been approved under OMB control
number 0910-0338.

III. Electronic Access

    Persons with access to the internet may obtain the guidance at
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances,
https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

    Dated: August 3, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-16930 Filed 8-7-23; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 80, Number 182 (Monday, September 21, 2015)]
[Notices]
[Page 56973]
[FR Doc No: 2015-23533]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER15-2453-000]

 Passadumkeag Windpark, LLC; Supplemental Notice That Initial
Market-Based Rate Filing Includes Request for Blanket Section 204
Authorization

    This is a supplemental notice in the above-referenced proceeding of
Passadumkeag Windpark, LLC's application for market-based rate
authority, with an accompanying rate tariff, noting that such
application includes a request for blanket authorization, under 18 CFR
part 34, of future issuances of securities and assumptions of
liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is September 21, 2015.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
5 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for electronic review in the
Commission's Public Reference Room in Washington, DC. There is an
eSubscription link on the Web site that enables subscribers to receive
email notification when a document is added to a subscribed docket(s).
For assistance with any FERC Online service, please email
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.

    Dated: August 31, 2015.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2015-23533 Filed 9-18-15; 8:45 am]
 BILLING CODE 6717-01-P


Comment Info: =================

General Comment:I would like to request a 105 day extension to the commenting period for the e-cigarette regulations. I have been away from tobacco products for well over a year with the help of these tobacco free products. Long with this request I would like to say that I also request you change this regulation to relax greatly the restrictions you have proposed. These products help people. Thanks for your time.   Michael Vought


Total hours and cost Information Collection Activity Engineer @ 64.28/ hr Manager @

$ 96.96/ hr Legal @

$ 108.84/ hr Clerical@

$ 31.06/ hr Respon.

hr/ yr Labor Cost/ yr Capital Startup Cost O & M Cost( 1) Applications/ r espondent Number of Respon. Total hr/ yr Total Cost/ yr Review of regulations 5 1 1 0 7 527 0 10 1.0 1 7 537 Other precertificatio n activities 34 5 1 0 40 2,779 0 100 1.0 1 40 2,879 Testing oversight 14 0 0 0 14 900 0 0 1.0 1 14 900 Test Cost ( annualized) 0 0 0 0 0 0 0 33,333 1.0 1 0 33,333 Additional testing cost to equipment's estimate lifetime cost 0 0 0 0 0 0 0 1,333 1.0 1 1,333 Preparing and submitting certification application 21 2 0 4 27 1,668 0 40 1.0 1 27 1,708 Preparing and supporting running changes 1 0 0 1 2 95 0 10 1.0 1 2 105 Store, file and maintain records 3 0 0 20 23 814 0 10 1.0 1 23 824 Audit Compliance 8 5 1 2 16 1,170 0 100 1.0 1 16 1,270 Total per respondent 86 13 3 27 129 7,954 0 varies varies N/ A N/ A N/ A Total for the industry N/ A N/ A N/ A N/ A N/ A $ 7,954 0 $ 34,936 varies 1 129 $ 42,890 ( 1) See section 6( b) ii for details. Table 1 Annual Respondent Burden and Cost  Pre 1993 Urban Bus Retrofit Program Retrofit Equipment Manufacturers Hours and cost per application Total hours and cost Information Collection Activity Engineer @ 64.28/ hr Manager @

$ 96.96/ hr Legal @

$ 108.84/ hr Clerical@

$ 31.06/ hr Respon.

hr/ yr Labor Cost/ yr Capital Startup Cost O & M Cost( 1) Number of Respon. Total hr/ yr Total Cost/ yr Review of regulations 5 2 3 0 10 842 0 10 40 400 34,074 Maximum life cycle cost of equipment .1 g/ bhp hr standard 0 0 0 0 0 0 0 3,552 15 0 53,280 Maximum cost  25%

PM reduction option 0 0 0 0 0 0 0 895 25 0 22,375 Store, file and maintain records 3 0 0 20 23 814 0 10 40 920 32,962 Audit Compliance 5 1 1 1 8 558 0 10 1 8 568 Total per respondent 13 3 4 21 41 2,214 0 varies N/ A N/ A N/ A Total for the industry N/ A N/ A N/ A N/ A N/ A $ 66,793 0 $ 76,465 40 1,328 $ 143,258 ( 1) See section 6( b) ii for details. Table 2 Annual Respondent Burden and Cost  Pre 1993 Urban Bus Retrofit Program Urban Bus Operators Hours and cost per application Information Collection Activity Engineer @

$ 60.82/ hr Attorney @

$ 66.34/ hr Respon.

hr/ yr Labor cost/ yr Capital Startup Cost O & M Cost( 1) Number of Respon. Total hr/ yr Total cost/ yr Review regulations 3 1 4 107 0 0 1 4 107 Process Certification Application 42 1 43 1100 0 3 1 43 1,103 Equiment Manufacturer Audit 13 1 14 361 0 500 1 14 861 Bus Operator Audit 13 1 14 361 0 500 1 14 861 Recordkeeping 2 0 2 51 0 0 1 2 51 Total per respondent 73 4 77 1,980 0 1,003 N/ A N/ A N/ A Total for the industry N/ A N/ A N/ A $ 1,980 0 $ 1,003 1 77 $ 2,983 ( 1) See section 6 ( c ) for details. Table 3 Pre 1993 Urban Bus Retrofit Program Annual Agency Burden and Cost Hours and cost per application Total hours and cost


[Federal Register Volume 79, Number 34 (Thursday, February 20, 2014)]
[Notices]
[Page 9736]
[FR Doc No: 2014-03648]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER14-1309-000]

Singer Energy Group, LLC; Supplemental Notice That Initial
Market-Based Rate Filing Includes Request for Blanket Section 204
Authorization

    This is a supplemental notice in the above-referenced proceeding of
Singer Energy Group, LLC's application for market-based rate authority,
with an accompanying rate tariff, noting that such application includes
a request for blanket authorization, under 18 CFR Part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR Part 34, of future issuances of securities and assumptions of
liability, is March 4, 2014.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
5 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for review in the Commission's
Public Reference Room in Washington, DC. There is an eSubscription link
on the Web site that enables subscribers to receive email notification
when a document is added to a subscribed docket(s). For assistance with
any FERC Online service, please email<EMAIL_ADDRESS>or
call<PHONE_NUMBER> (toll free). For TTY, call<PHONE_NUMBER>.

    Dated: February 12, 2014.
Kimberly D. Bose,
Secretary.
[FR Doc. 2014-03648 Filed 2-19-14; 8:45 am]
BILLING CODE 6717-01-P


"richardastrust.com"<EMAIL_ADDRESS> 08/29/2007 01:37 PMTo

Margaret Sheppard/DC/USEPA/US@EPA, george<EMAIL_ADDRESS>

cc

bcc

Subject

Fwd: RE: refrigerant guidelines

For Follow Up:

Normal Priority

 History:

This message has been forwarded.

Margaret

Looks like this is all they have. I spoke with Barry Lyons of BOC this morning. He said there is a woman, Jane Gartshore, of Cool Concerns who gives the class on hydrocarbon refrigerant. CARE sends their technicians to her for training on hydrocarbon refrigerants. I spoke to her and she told me she follows the attached guideline and uses slides about the Cool refrigerants and hands out the ACRIB_HC_Guide which is covered in the class.

Steve Hammerling of ASHRAE said they do not have anything in place for Hydrocarbon Refrigerant since it is not legal in the U.S.  Once legal, they will put guidelines in place.

Richard

"Lyons,Barry"<EMAIL_ADDRESS>wrote:

Subject: RE: refrigerant guidelines

Date: Wed, 29 Aug 2007 09:08:34 +0100

From: "Lyons,Barry"<EMAIL_ADDRESS> To: "richardastrust.com"<EMAIL_ADDRESS>

Richard

Hope this helps

Regards

Barry J Lyons F.Inst. R

Business Development Manager

BOC Refrigerants

DL +44 (0) 1483 244654 | Mob +44 (0) 7920 591216

The BOC Group The Surrey Research Park, Guildford, Surrey GU2 7XY

www.bocrefrigerants.com |<EMAIL_ADDRESS> Sent from The BOC Group plc, registered in England and Wales No. 22096, or its subsidiary, BOC Limited, registered in England and Wales No. 337663 members of the Linde Group. Registered office of both companies Chertsey Road, Windlesham, Surrey, GU20 6HJ, England

From: richardastrust.com<EMAIL_ADDRESS> Sent: 29 August 2007 6:34 AM

To: Lyons,Barry

Subject: refrigerant guidelines

Dear Barry:

My name is Richard Maruya and I have a hydrocarbon refrigerant for which I've applied to the U.S. EPA Alternative Refrigerant division for a clearance.

The EPA is asking for a training guideline on Hydrocarbon Refrigerant as well as a safety guideline  which they do not have. I understand that CARE has one. Would you please send me a copy to submit to the EPA for a standard?

Thank you,

Richard Maruya

Richard Maruya

phone<PHONE_NUMBER>

fax<PHONE_NUMBER>

cell<PHONE_NUMBER>

e mail<EMAIL_ADDRESS>or<EMAIL_ADDRESS>

CONFIDENTIALITY NOTICE This e-mail may contain confidential or privileged information, if you are not the intended recipient, or the person responsible for delivering the message to the intended recipient, then please notify us by return e-mail immediately. Should you have received this e-mail in error then you should not copy this for any purpose nor disclose its contents to any other person.

_____________________________________________________________________

This e-mail has been scanned for viruses by Verizon Business Internet Managed Scanning Services - powered by MessageLabs. For further information visit http://www.verizonbusiness.com/uk

***********************************************************************

The information contained in this email and any attachments may be confidential and is provided solely for the use of the intended recipient(s). If you are not the intended recipient, you are hereby notified that any disclosure, distribution, or use of this e-mail, its attachments or any information contained therein is unauthorised and prohibited. If you have received this in error, please contact the sender immediately and delete this e-mail and any attachments.

No responsibility is accepted for any virus or defect that might arise from opening this e-mail or attachments, whether or not it has been checked by anti-virus software.

Richard Maruya

phone<PHONE_NUMBER>

fax<PHONE_NUMBER>

cell<PHONE_NUMBER>

e mail<EMAIL_ADDRESS>or<EMAIL_ADDRESS>

CONFIDENTIALITY NOTICE This e-mail may contain confidential or privileged information, if you are not the intended recipient, or the person responsible for delivering the message to the intended recipient, then please notify us by return e-mail immediately. Should you have received this e-mail in error then you should not copy this for any purpose nor disclose its contents to any other person.


[Federal Register Volume 83, Number 83 (Monday, April 30, 2018)]
[Rules and Regulations]
[Pages 18727-18730]
[FR Doc No: 2018-08654]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2018-0305; Product Identifier 2013-NM-226-AD; Amendment
39-19259; AD 2018-09-03]
RIN 2120-AA64

Airworthiness Directives; Airbus Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; request for comments.

-----------------------------------------------------------------------

SUMMARY: We are superseding Airworthiness Directive (AD) 2009-11-08,
which applied to certain Airbus Model A330-202, -223, -243, -301, -322,
and -342 airplanes. AD 2009-11-08 required repetitive special detailed
(high frequency eddy current) inspections to detect cracking of the
keel beam fitting horizontal flange edge at a certain frame (FR) on the
left- and right-hand sides of the fuselage, and repair if necessary.
This AD was prompted by a new fatigue and damage tolerance evaluation
that concluded the current inspection thresholds and intervals had to
be modified. This AD requires contacting the FAA to obtain instructions
for addressing the unsafe condition on these products, and doing the
actions specified in those instructions. We are issuing this AD to
address the unsafe condition on these products.

DATES: This AD becomes effective May 15, 2018.
    We must receive comments on this AD by June 14, 2018.

ADDRESSES: You may send comments, using the procedures found in 14 CFR
11.43 and 11.45, by any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.

Examining the AD Docket

    You may examine the AD docket on the internet at http://www.regulations.gov by searching for and locating Docket No. FAA-2018-
0305; or in person at the Docket Operations office between 9 a.m. and 5
p.m., Monday through Friday, except Federal holidays. The AD docket
contains this AD, the regulatory evaluation, any comments received, and
other information. The street address for the Docket Operations office
(telephone:<PHONE_NUMBER>) is in the ADDRESSES section. Comments will be
available in the AD docket shortly after receipt.

FOR FURTHER INFORMATION CONTACT: Vladimir Ulyanov, Aerospace Engineer,
International Section, Transport Standards Branch, FAA, 2200 South
216th Street, Des Moines, WA 98198; telephone and fax:<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Discussion

    We issued AD 2009-11-08, Amendment 39-15918 (74 FR 25404, May 28,
2009) (``AD 2009-11-08''), which applied to certain Airbus Model A330-
202, -223, -243, -301, -322, and -342 airplanes. AD 2009-11-08 was
prompted by reports of cracks on the left- and right-hand sides between
the crossing area of the keel angle fitting and the front spar of the
center wing box. AD 2009-11-08 required a special detailed (high
frequency eddy current) inspection to detect cracking of the keel beam
fitting horizontal flange edge at FR40 on the left- and right-hand
sides of the fuselage, and repair if necessary. We issued AD 2009-11-08
to detect and correct cracking on the left- and right-hand sides,
between the crossing area of the keel angle fitting and the front spar
of the center wing box, which if not corrected, could affect the
structural integrity of the airplane.
    Since we issued AD 2009-11-08, a new fatigue and damage tolerance
evaluation was conducted by the manufacturer. It was concluded that,
due to airplane utilization, the current inspection thresholds and
intervals had to be modified.
    The European Aviation Safety Agency (EASA), which is the Technical
Agent for the Member States of the European Union, has issued EASA AD
2013-0247, dated October 10, 2013 (referred to after this as the
Mandatory Continuing Airworthiness Information, or ``the MCAI''), to
correct an unsafe condition for certain Airbus Model A330-202, -223, -
243, -301, -322, and -342 airplanes. The MCAI states:

    During the A330 and A340 aeroplane fatigue test, cracks appeared
on the right and left sides between the crossing area of the keel
angle fitting and the front spar of the Centre Wing Box (CWB).
Several modifications were introduced in the fleet in the area of
frame (FR) 40 keel angle assembly in order to prevent these cracks.
However, the new design caused interference between one fastener and
the keel angle which was corrected by further local reprofiling of
the keel angle horizontal flange.
    This condition, if not detected and corrected, could result in
reduced structural integrity of the area.
    Prompted by these findings, EASA issued AD 2008-0213 [which
corresponds to FAA AD 2009-11-08] to require accomplishment of
repetitive special detailed inspection on the horizontal flange of
the keel beam in the area of first fastener hole aft of FR40 and,
depending on findings, accomplishment of a repair.
    Since that [EASA] AD was issued, a new fatigue and damage
tolerance evaluation was conducted by Airbus. It was concluded that,
due to aeroplane utilisation, the current inspection thresholds and
intervals had to be modified.
    For the reason described above, this [EASA] AD retains the
requirements of EASA AD 2008-0213, which is superseded, and
redefines the thresholds and intervals.

    You may examine the MCAI on the internet at http://www.regulations.gov by searching for and locating Docket No. FAA-2018-
0305.

FAA's Determination and Requirements of This AD

    This product has been approved by the aviation authority of another
country, and is approved for operation in the United States. Pursuant
to our bilateral agreement with the State of Design Authority, we have
been notified of the unsafe condition described in the MCAI. We are
issuing this AD because we evaluated all pertinent information and
determined the unsafe condition exists and is likely to exist or
develop on other products of the same type design.

FAA's Determination of the Effective Date

    Since there are currently no domestic operators of this product, we
find good cause that notice and opportunity for prior public comment
are unnecessary. In addition, for the reason(s) stated above, we find
that good cause exists for making this amendment effective in less than
30 days.

Comments Invited

    This AD is a final rule that involves requirements affecting flight
safety, and we did not precede it by notice and opportunity for public
comment. We invite you to send any written relevant data, views, or
arguments about this AD. Send your comments to an address listed under
the ADDRESSES section. Include ``Docket No. FAA-2018-0305; Product
Identifier 2013-NM-226-AD'' at the beginning of your comments. We
specifically invite comments on the overall regulatory, economic,
environmental, and energy aspects of this AD. We will consider all
comments received by the closing date and may amend this AD based on
those comments.
    We will post all comments we receive, without change, to http://www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this AD.

Costs of Compliance

    Currently, there are no affected U.S.-registered airplanes. This AD
requires contacting the FAA to obtain instructions for addressing the
unsafe condition, and doing the actions specified in those
instructions. Based on the actions specified in the MCAI AD, we are
providing the following cost estimates for an affected airplane that is
placed on the U.S. Register in the future:

                                                 Estimated Costs
----------------------------------------------------------------------------------------------------------------
                                                                                Cost per      Cost on U.S.
                Action                         Labor cost           Parts cost        product        operators
----------------------------------------------------------------------------------------------------------------
Inspection [new action]...............  9 work-hours x $85 per                $0            $765              $0
                                         hour = $765.
----------------------------------------------------------------------------------------------------------------

    We have received no definitive data that would enable us to provide
cost estimates for the on-condition actions specified in the MCAI AD.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.
    This AD is issued in accordance with authority delegated by the
Executive Director, Aircraft Certification Service, as authorized by
FAA Order 8000.51C. In accordance with that order, issuance of ADs is
normally a function of the Compliance and Airworthiness Division, but
during this transition period, the Executive Director has delegated the
authority to issue ADs applicable to transport category airplanes to
the Director of the System Oversight Division.

Regulatory Findings

    We determined that this AD will not have federalism implications
under Executive Order 13132. This AD will not have a substantial direct
effect on the States, on the relationship between the national
government and the States, or on the distribution of power and
responsibilities among the various levels of government.
    For the reasons discussed above, I certify that this AD:
    1. Is not a ``significant regulatory action'' under Executive Order
12866;
    2. Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979);
    3. Will not affect intrastate aviation in Alaska; and
    4. Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

Adoption of the Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13   [Amended]

0
2. The FAA amends Sec.  39.13 by removing airworthiness directive (AD)
2009-11-08, Amendment 39-15918 (74 FR 25404, May 28, 2009), and adding
the following new AD:

2018-09-03 Airbus: Amendment 39-19259; Docket No. FAA-2018-0305;
Product Identifier 2013-NM-226-AD.

(a) Effective Date

    This AD becomes effective May 15, 2018.

(b) Affected ADs

    This AD replaces AD 2009-11-08, Amendment 39-15918 (74 FR 25404,
May 28, 2009) (``AD 2009-11-08'').

(c) Applicability

    This AD applies to Airbus Model A330-202, -223, -243, -301, -
322, and -342 airplanes, certificated in any category, manufacturer
serial numbers: 0177, 0181, 0183, 0184, 0188, 0189, 0191, 0195,
0198, 0200, 0203, 0205, 0206, 0209, 0211, 0219, 0222, 0223, 0224,
0226, 0229, 0230, 0231, 0232, 0234, 0238, 0240, 0241, 0244, 0247,
0248, 0249, 0250, 0251, 0253, 0254, and 0255.

(d) Subject

    Air Transport Association (ATA) of America Code 53, Fuselage.

(e) Reason

    This AD was prompted by reports of cracks on the left- and
right-hand sides between the crossing area of the keel angle fitting
and the front spar of the center wing box and by a new fatigue and
damage tolerance evaluation that concluded the current inspection
thresholds and intervals had to be modified. We are issuing this AD
to detect and correct cracking on the left- and right-hand sides
between the crossing area of the keel angle fitting and the front
spar of the center wing box, which if not corrected, could affect
the structural integrity of the airplane.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Required Actions

    Within 30 days after the effective date of this AD, request
instructions from the Manager, International Section, Transport
Standards Branch, FAA, to address the unsafe condition specified in
paragraph (e) of this AD; and accomplish the actions at the times
specified in, and in accordance with, those instructions. Guidance
can be found in Mandatory Continuing Airworthiness Information
(MCAI) European Aviation Safety Agency (EASA) AD 2013-0247, dated
October 10, 2013.

(h) Alternative Methods of Compliance (AMOCs)

    The Manager, International Section, Transport Standards Branch,
FAA, has the authority to approve AMOCs for this AD, if requested
using the procedures found in 14 CFR 39.19. In accordance with 14
CFR 39.19, send your request to your principal inspector or local
Flight Standards District Office, as appropriate. If sending
information directly to the International Section, send it to the
attention of the person identified in paragraph (i)(2) of this AD.
Information may be emailed to: [email protected].
Before using any approved AMOC, notify your appropriate principal
inspector, or lacking a principal inspector, the manager of the
local flight standards district office/certificate holding district
office.

(i) Related Information

    (1) Refer to MCAI EASA AD 2013-0247, dated October 10, 2013, for
related information. You may examine the MCAI on the internet at
http://www.regulations.gov by searching for and locating Docket No.
FAA-2018-0305.
    (2) For more information about this AD, contact Vladimir
Ulyanov, Aerospace Engineer, International Section, Transport
Standards Branch, FAA, 2200 South 216th Street, Des Moines, WA
98198; telephone and fax:<PHONE_NUMBER>.

(j) Material Incorporated by Reference

    None.

    Issued in Des Moines, Washington, on April 17, 2018.
Michael Kaszycki,
Acting Director, System Oversight Division, Aircraft Certification
Service.
[FR Doc. 2018-08654 Filed 4-27-18; 8:45 am]
BILLING CODE 4910-13-P